Skip to main content
main-content
Top

Tip

Swipe om te navigeren naar een ander artikel

07-01-2021 | Original Article | Uitgave 3/2021 Open Access

Netherlands Heart Journal 3/2021

Characteristics of patients with atrial fibrillation prescribed edoxaban in Belgium and the Netherlands: insights from the ETNA-AF-Europe study

Tijdschrift:
Netherlands Heart Journal > Uitgave 3/2021
Auteurs:
T. A. C. de Vries, M. E. W. Hemels, F. Cools, H. J. G. M. Crijns, L. Yperzeele, P. Vanacker, I. Blankoff, P. Lancellotti, G. H. Mairesse, A. de Veer, R. Casado Arroyo, E. Catez, M. de Pauw, T. Vanassche, C. de Asmundis, P. Kirchhof, R. De Caterina, J. R. de Groot, the ETNA-AF-Europe principal investigators from Belgium and the Netherlands*
Belangrijke opmerkingen

Electronic supplementary material

The online version of this article (https://​doi.​org/​10.​1007/​s12471-020-01518-7) contains supplementary material, which is available to authorized users.
*See supplementary material for the principal investigators of ETNA-AF-Europe from Belgium and the Netherlands.
This article has been published in two journals by kind permission of the editors and publishers. The text of the article is the same in both publications. This article is also available at https://​doi.​org/​10.​1080/​00015385.​2020.​1746095.

Abstract

Background

Studies on the use of non-vitamin K antagonist oral anticoagulants in unselected patients with atrial fibrillation (AF) show that clinical characteristics and dosing practices differ per region, but lack data on edoxaban.

Methods

With data from Edoxaban Treatment in routiNe clinical prActice for patients with AF in Europe (ETNA-AF-Europe), a large prospective observational study, we compared clinical characteristics (including the dose reduction criteria for edoxaban: creatinine clearance 15–50 ml/min, weight ≤60 kg, and/or use of strong p‑glycoprotein inhibitors) of patients from Belgium and the Netherlands (BeNe) with those from other European countries (OEC).

Results

Of all 13,639 patients in ETNA-AF-Europe, 2579 were from BeNe. BeNe patients were younger than OEC patients (mean age: 72.3 vs 73.9 years), and had lower CHA2DS2-VASc (mean: 2.8 vs 3.2) and HAS-BLED scores (mean: 2.4 vs 2.6). Patients from BeNe less often had hypertension (61.6% vs 80.4%), and/or diabetes mellitus (17.3% vs 23.1%) than patients from OEC. Moreover, relatively fewer patients in BeNe were prescribed the reduced dose of 30 mg edoxaban (14.8%) than in OEC (25.4%). Overall, edoxaban was dosed according to label in 83.1% of patients. Yet, 30 mg edoxaban was prescribed in the absence of any dose reduction criteria in 36.9% of 30 mg users (5.5% of all patients) in BeNe compared with 35.5% (9.0% of all patients) in OEC.

Conclusion

There were several notable differences between BeNe and OEC regarding clinical characteristics and dosing practices in patients prescribed edoxaban, which are relevant for the local implementation of dose evaluation and optimisation.

Trial registration

NCT02944019; Date of registration 24 October 2016

Onze productaanbevelingen

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Extra materiaal
Literatuur
Over dit artikel

Andere artikelen Uitgave 3/2021

Netherlands Heart Journal 3/2021 Naar de uitgave